3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome
1
Neoplastic Processes
1
Myeloproliferative Disorders
1
Leukemia
1
Hematologic Diseases
1
Bronchiolitis Obliterans Syndrome
1
Bone Marrow Diseases
1
Interventions
blinatumomab
3
Cytarabine
3
venetoclax
2
revumenib
2
Daunorubicin
2
quizartinib
1
obinutuzumab
1
nilotinib
1
ivosidenib
1
etoposide phosphate
1
bosutinib
1
acalabrutinib
1
Mitoxantrone
1
Midazolam
1
Itraconazole
1
Imatinib Mesylate
1
Idarubicin
1
Gemtuzumab
1
Etoposide
1
Drug Therapy
1
Cobicistat
1
Azacitidine
1
Asparaginase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Leukemia
×
nilotinib
×
Clear all
NCT01844765
2021-04-22
DIALOG
Novartis
Phase 2
Completed
59 enrolled
33 charts
1 FDA